NASDAQ: EDIT · Life Sciences · 5 alerts · CIK 1650664
Share price
$1.87Close, Nov 16
Market cap
$289M
Shares outstanding
154.34MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Editas Medicine, Inc. filings on SEC EDGAR ↗
Editas Medicine CEO Gilmore Neil O'Neill Sells $51.1K of Stock
Gilmore Neil O'Neill, CEO, sold 21,164 shares of Editas Medicine, Inc. at $2.42 a share, worth $51.1K in total on Nov 11, 2026. Shares held after the trade: 265,592 (-7.4%).
Editas Medicine EVP, CSO Linda Burkly Sells $18.9K of Stock
Linda Burkly, EVP, CSO, sold 7,814 shares of Editas Medicine, Inc. at $2.42 a share, worth $18.9K in total on Nov 11, 2026. Shares held after the trade: 70,379 (-10.0%).
Editas Medicine reported a net loss of $23.4 million for the third quarter of 2026, a significant improvement from the $154.4 million loss in the prior year period which was impacted by restructuring charges. The company strengthened its balance sheet through a $116.9 million common stock and warrant financing, ending the period with $190.2 million in cash, cash equivalents, and marketable securities.
Editas Medicine reported Q3 2026 financial results, highlighting a cash runway extending into the second half of 2028. The company received regulatory approval to initiate its Phase 1/2 Strive study for EDIT-401 in Australia and triggered a milestone payment from Bristol Myers Squibb following the acceptance of a second IND/CTA for their CAR T collaboration.
Term
Q3 2026
“We are incredibly excited by the progress we made in the third quarter as we advanced EDIT-401, our potentially best-in-class in vivo gene editing medicine for hyperlipidemia, towards the clinic.”
Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer